Human Metapneumovirus (hMPV) Therapeutics Industry Valued at $0.89 Billion by 2029 With CAGR of 6.2% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Human Metapneumovirus (hMPV) Therapeutics Market from 2024 to 2025?
The market size of human metapneumovirus (hMPV) therapeutics has seen significant growth in recent years. It is forecasted to expand from $0.66 billion in 2024 to $0.70 billion in 2025, growing at a compound annual growth rate (CAGR) of 6.6%. The previous growth can be credited to heightened awareness of viral respiratory infections, the growing number of pediatric respiratory illness cases, an increase in hospitalization rates, global efforts to monitor public health, and an increased research emphasis on newly emerging respiratory viruses.
What Is the Projected Market Size of the Human Metapneumovirus (hMPV) Therapeutics Market?
The market for therapeutics targeting the human metapneumovirus (hMPV) is predicted to experience significant expansion in the forthcoming years, with a forecasted value of $0.90 billion in 2029, reflecting a compound annual growth rate (CAGR) of 6.2%. Several variables contribute to this projected growth during the forecast period, including the increasing requirement for supportive care treatments, heightened funding from governmental bodies and NGOs, greater awareness related to respiratory infections, rising conditions of pediatric respiratory disease, and a surge in demand for specific therapies. Key emerging trends for this period involve technology integration into diagnostic frameworks, technological progression in developing antiviral drugs, advances in researching vaccines and their delivery systems, cutting-edge point-of-care testing driven by technology, and improvements in molecular diagnostics.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23420&type=smp
Who are the Major Competitors in the Human Metapneumovirus (hMPV) Therapeutics Market Outlook?
Major companies operating in the human metapneumovirus (hMPV) therapeutics market are Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Riverside Health System, Narayana Health, Vir Biotechnology Inc., Fortis Healthcare, Apollo Diagnostics, Pathkind Diagnostics Pvt Ltd, Max Healthcare, LalPathLabs, Bio Farma, Metropolis Healthcare, American Lung Association, Enanta Pharmaceuticals Inc. , Regency Healthcare, The Native Antigen Company, Max Lab, Agilus Diagnostics
What Is Fueling Growth in the Human Metapneumovirus (hMPV) Therapeutics Market?
The growth of the human metapneumovirus (HMPV) therapeutics market is anticipated to be propelled by the escalating occurrence of respiratory infections. These infections manifest in the respiratory tract, consisting of air passages, lungs, throat, and nose, and their growing numbers can be attributed to increased levels of air pollution. Respiratory irritants such as particulate matter and nitrogen dioxide exacerbate and debilitate the respiratory tract, heightening an individual’s susceptibility to infection. HMPV therapeutics play a crucial role in tackling respiratory infections instigated by hMPV through the reduction of viral replication and inflammation with antiviral treatments and ancillary care, enhancing health outcomes for vulnerable populations like the elderly, infants, and those with a compromised immune system. As an illustration, in June 2024, a report by the Australia-based government agency, the Australian Institute of Health and Welfare, revealed that Chronic Obstructive Pulmonary Disease (COPD) in Australia accounted for 3.6% of the total disease burden in the previous year, representing 50% of the cumulative burden from respiratory diseases; with an estimated 638,000 individuals (2.5% of the population) living with COPD in 2022. Consequently, the surge in respiratory infections significantly contributes to the expansion of the human metapneumovirus (HMPV) therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23420&type=smp
Which Human Metapneumovirus (hMPV) Therapeutics Market Segments Are Growing the Fastest?
The human metapneumovirus (hMPV) therapeutics market covered in this report is segmented –
1) By Drug Class: Antipyretic, Decongestants, Cough Suppressants, Other Drug Class
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-Use: Hospitals And Clinics, Diagnostic And Reference Laboratories, Academic And Research Institutions, Other End-Uses
Subsegments:
1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)
2) By Decongestants: Nasal Decongestants, Oral Decongestants
3) By Cough Suppressants: Dextromethorphan, Codeine, Benzonatate
4) By Other Drug Class: Antiviral Agents, Antibiotics (if secondary bacterial infection occurs), Inhaled Corticosteroids
Which Industry Trends Are Shaping the Future of the Human Metapneumovirus (hMPV) Therapeutics Market?
Leading businesses in the human metapneumovirus (hMPV) therapeutics market are strategizing on developing specialized antiviral therapies, such as monoclonal antibodies. These antibodies are designed in a lab and can replicate the natural disease-fighting capabilities of the immune system. They provide specific treatments for a range of diseases, such as cancer and autoimmune disorders, by binding to and neutralizing damaging antigens or cells. To illustrate, Vicebio Ltd., a biopharmaceutical firm from the UK, bagged $100 million in Series B fundraising in October 2024. This was orchestrated by TCGX, with contributions from Goldman Sachs Alternatives and other participants. The funds will help further the Phase 1 clinical experiment of VXB-241. This is a dual-action vaccine aimed at RSV and hMPV, with preliminary findings projected for mid-2025. Moreover, the development of VXB-251, a three-pronged vaccine combating RSV, hMPV, and Parainfluenza Virus 3, will be expedited. This vaccine is aimed at tackling crucial health issues among the elderly.
Access The Full Report Here:
Which Countries Are Leading the Human Metapneumovirus (hMPV) Therapeutics Market?
North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human metapneumovirus (hMPV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23420
This Report Delivers Insight On:
1. How big is the human metapneumovirus (hmpv) therapeutics market, and how is it changing globally?
2. Who are the major companies in the human metapneumovirus (hmpv) therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the human metapneumovirus (hmpv) therapeutics market right now?
4. Which products or customer segments are growing the most in the human metapneumovirus (hmpv) therapeutics market?
5. What factors are helping or slowing down the growth of the human metapneumovirus (hmpv) therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
